Sanofi, Spectrum Settle Patent Suit on Rolontis Treatment

Sanofi’s Bioverativ unit settled a lawsuit with Spectrum Pharmaceuticals Inc., whose proposed Rolontis—a drug used to treat a condition caused by chemotherapy that leaves patients more susceptible to infections—it had accused of infringing three patents.

Bioverativ and Spectrum dropped all claims and counterclaims with prejudice, but no details of the settlement were provided in the dismissal order approved Wednesday in the U.S. District Court for the District of Delaware.

On Feb. 18, Sanofi’s Genzyme and Bioverativ told the U.S. International Trade Commission that they were withdrawing a patent-infringement complaint they had filed in December because they had reached a ...